Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease

To evaluate the efficacy of Lyophilized Human Amnion Membrane Disc in reducing corneal epithelial damage as measured by the Lexitas Modified National Eye Institute (NEI) Grading Scale for Corneal Fluorescein Staining.

Participants needed: 50
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Cellution BiologicsUpdated: Aug 6, 2026
Eligibility criteria

18 years of age or older. [+7]

Presence of persistent corneal epithelial defect or ulcer in either eye [+14]

Status: Not yet recruiting

Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns

This study will evaluate the efficacy of a dehydrated human placental tissue product, commercially labeled as AmCoreMatrix Burn ™ versus SOC in the closure of partial thickness burns. Human Cellular and Tissue based Products (HCT/Ps), specifically Dehydrated Human Amnion - Intermediate Layer - Chorion Membrane (dHAICM) offer a multimodal biological approach to burn management. Unlike synthetic dressings or silver-based creams, dHAICM serves as a sophisticated bioactive scaffold. It is a minimally manipulated allograft that provides superior tensile strength and barrier function compared to single-layer membranes. This study aims to document its performance in hospital burn units.

Participants needed: 70
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Cellution BiologicsUpdated: Aug 6, 2026
Eligibility criteria

18 years of age or older [+5]

Full thickness burns. [+19]

Status: Not yet recruiting

Evaluation of the Safety and Efficacy of Dehydrated Human Placenta Tissue (dHPT) for Wound Healing

The retrospective trial is observational, intended to stand alone, complement and integrate data collected in ongoing clinical studies to aid in establishing payor coverage in the United States (U.S.) for Cellution Biologics allograft products with real-world evidence to support the clinical adoption in patients to manage chronic or surgical wounds.

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Cellution BiologicsUpdated: Mar 3, 2026
Eligibility criteria

18 years of age or older. [+5]

AmchoPlast dHPT product was not applied to wound. [+4]